Abstract

Allowing Compounding Pharmacies to Address Drug Shortages

Author(s): Broughel James

Issue: Mar/Apr 2022 - Volume 26, Number 2

Page(s): 100-109

Download in electronic PDF format for $75

Abstract

The U.S. has entered a new age of supply chain challenges, and while many of these challenges were unpredictable consequences of the COVID-19 pandemic, there are also some predictable shortages, including those that arise in the modern prescription drug market. In an effort to combat these foreseeable events, compounding pharmacies, or compounders, have the wherewithal to step in and address drug shortages when they occur. Whether they are able to assist, however, ultimately hinges not on their capabilities, but on whether they are allowed to assist under federal law.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2022 Pg. 100-109	Allowing Compounding Pharmacies to Address Drug Shortages Author(s): Broughel James
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Sep/Oct 2014 Pg. 379-380	Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Author(s): Blankenship Cynthia E
Jul/Aug 2020 Pg. 287-295	Pharmacies on the Frontline: Responding to the COVID-19 Pandemic Author(s): McElhiney Linda F
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Mar/Apr 2022 Pg. 92	PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry" Author(s): Allen Loyd V Jr
Jul/Aug 2022 Pg. 298-301	The Role of Compounding Pharmacists During Drug Shortages Author(s): Ofei Kelvin
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Jul/Aug 2012 Pg. 294-298	Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers Author(s): Allen Loyd V Jr, Williams LaVonn A
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Nov/Dec 2012 Pg. 456-460	Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Author(s): Lyon Joanna
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
May/Jun 2023 Pg. 180	PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again! Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G